Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund.
Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies.
iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development
Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala.
AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy
Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases.
iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies.
With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial.
In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy.
To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research.
iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression.
About iRegene Therapeutics
iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide.
In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Colle AI Optimizes Asset Transfer Engines for Better NFT Routing Flow
Platform introduces intelligent enhancements to streamline cross-chain asset movement and improve NFT distribution performance Singapore, Singapore--(Newsfile Corp. - June 9, 2025) - Colle AI (COLLE), the AI-powered multichain platform for NFT creation, has rolled out major upgrades to its asset transfer engines, improving the flow and reliability of NFT routing across blockchain networks. This advancement marks another step in Colle AI's mission to simplify Web3 creation through intelligent infrastructure. The optimized transfer engine leverages adaptive routing logic to enhance NFT movement across chains like Ethereum, Solana, Bitcoin, XRP, and BNB Chain. It now auto-detects optimal pathways, adjusts to network conditions in real time, and dynamically balances fees and speed—giving users a seamless cross-chain experience with minimal technical overhead. With smarter synchronization and reduced latency, Colle AI's transfer upgrades empower creators to launch, move, and interact with NFTs without the delays and inconsistencies that often affect multichain platforms. Assets maintain integrity and availability across all networks with precision-engineered control built into the backend. This upgrade reflects Colle AI's continued focus on enabling frictionless NFT development and distribution. By optimizing the routing foundation, the platform strengthens its support for scalable projects, creator autonomy, and efficient asset liquidity in the evolving Web3 ecosystem. About Colle AI Colle AI leverages AI technology to simplify the NFT creation process, empowering artists and creators to easily transform their ideas into digital assets. The platform aims to make NFT creation more accessible, fostering innovation in the digital art space. Media Contact Dorothy Marley KaJ Labs +1 707-622-6168 media@ Social Media Twitter Instagram To view the source version of this press release, please visit
Cision Canada
2 hours ago
- Cision Canada
Markel International appoints Sucheng Chang to lead Asia Pacific operations
LONDON, June 9, 2025 /CNW/ -- Markel Insurance, the insurance operations within Markel Group Inc. (NYSE:MKL), today announced that it has appointed Sucheng Chang as its new Managing Director for Asia Pacific, with effect from 14 July. In his new role, Chang will head up Markel International's Asia Pacific business, which operates from its regional hub in Singapore and from offices in Australia, Hong Kong, China, India, Malaysia and Dubai. He will be responsible for leading the strategic direction of the business, centered on maximizing profitable growth and delivering exceptional client and broker service. Markel International's Asia Pacific business has witnessed significant expansion in recent years, following investment made as part of its Accelerate Asia Pacific strategy. Since 2019, GWP has increased by approximately 600%, underwriting profitability has improved and the number of employees in the region has increased by nearly 300%. Chang will take over from Christian Stobbs, who earlier this year announced his decision to leave the Asia Pacific region, remaining with Markel in another role. Commenting on Chang's appointment, Andrew McMellin, President of Markel International, said: "Sucheng is a highly strategic and well-respected leader within the Asia Pacific market, and I'm thrilled that he's joining Markel to lead our regional business in the next phase of its development. The Accelerate Asia Pacific strategy is a cornerstone of the profitable growth agenda at Markel International. I've no doubt that Sucheng's leadership qualities and his significant experience of scaling insurance operations in Asia will help us to build on this momentum as we push it forward to even greater success." Chang added: "Markel has made huge inroads in Asia Pacific and today is a well-respected insurance partner to clients and trading partners in the region, renowned for its focus on exceptional service and customer outcomes. I therefore couldn't be more excited to lead the next phase of the expansion of Markel's Asia Pacific business, building on the progress that's been made to expand our presence even further and take advantage of the opportunities available in the US$300-billion GWP Asia-Pacific insurance market." Chang arrives at Markel with significant experience scaling insurance operations across the Asia Pacific, most recently as Chief Executive Officer, Hong Kong, for Aon. Prior to joining Aon, Chang spent more than 13 years at Liberty Mutual in strategic roles, including Chief Distribution Officer, Global Retail Markets East and Chief Executive Officer of Liberty Insurance Singapore. He holds an MBA from Yale University and BA from Boston University. About Markel Insurance We are Markel Insurance, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we leverage a broad array of capabilities and expertise to create intelligent solutions for the most complex specialty insurance needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide.
Globe and Mail
2 hours ago
- Globe and Mail
Stocks Climb on Hopes of Easing US-China Trade Tensions
The S&P 500 Index ($SPX) (SPY) today is up +0.21%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.11%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.46%. June E-mini S&P futures (ESM25) are up +0.21%, and June E-mini Nasdaq futures (NQM25) are up +0.42%. Stock indexes recovered from early losses and are moving higher today, with the Nasdaq 100 reaching a 3 1/2-month high. Stocks are climbing on hopes that trade tensions will ease between the US and China after China's state media Xinhua News Agency reported that US President Trump and Chinese President Xi Jinping spoke by telephone today. President Xi agreed to more talks with Mr. Trump and urged the US to remove 'negative' measures that have roiled trade tensions between the two countries. The Chinese president also said the countries should work to reduce misunderstandings and that Trump was welcome to visit China. Stocks also garnered support from today's economic news that showed the US trade deficit in April shrank to a 20-month low, a positive factor for Q2 GDP. Stocks were under early pressure today on concerns about the US labor market after weekly jobless claims unexpectedly rose to a 7-3/4 month high. Also, today's downward revision to US Q1 nonfarm productivity and upward revision to Q1 unit labor costs were bearish for stocks. In addition, higher bond yields are negative for stocks as the 10-year T-note yield is up +3 bp to 4.39% as it rebounded from a 4-week low of 4.31% on negative carryover from a slide in 10-year German bunds after ECB President Lagarde said the ECB was nearing the end to its rate cutting cycle. US weekly initial unemployment claims unexpectedly rose +8,000 to a 7-3/4 month high of 247,000, showing a weaker labor market than expectations of a decline to 235,000. The US Apr trade deficit shrank to a 20-month low of -$61.6 billion, narrower than expectations of -$66.0 billion. US Q1 nonfarm productivity was revised lower to -1.5% from -0.8%. Q1 unit labor costs were revised upward to 6.6% from the previously reported 5.7%. Comments Wednesday evening from Minneapolis Fed President Kashkari signal he favors keeping interest rates steady when he said, 'The economy is seeming like it's pretty resilient so far, and so for me right now is the time to get data, see how the tariff negotiations shake out before we reach any firm conclusions about the direction of interest rates.' The markets are discounting the chances at 1% for a -25 bp rate cut at the next FOMC meeting on June 17-18. The markets this week will focus on any fresh trade or tariff news. On Friday, May nonfarm payrolls are expected to climb +125,000, and the May unemployment rate is expected to remain unchanged at 4.2%. Finally, May average hourly earnings are expected to rise +0.3% m/m and +3.7% y/y. Overseas stock markets today are mixed. The Euro Stoxx 50 is up +0.02%. China's Shanghai Composite climbed to a 1-1/2 week high and closed up +0.23%. Japan's Nikkei Stock 225 closed down -0.51%. Interest Rates September 10-year T-notes (ZNU2 5) today are down -5 ticks. The 10-year T-note yield is up +3.0 bp to 4.385%. Sep T-notes today fell from a 4-week high, and the 10-year T-note yield rose from a 4-week low of 4.310% and is moving higher. T-notes gave up early gains today and turned lower as stocks rallied on hopes of easing US-Chian trade tensions after the Xinhua news agency reported that President Trump and President Xi Jinping spoke by telephone today. T-notes also have a negative carryover from a slide in 10-year German bunds on hawkish comments from ECB President Lagarde, who said the ECB is nearing the end of its rate-cutting cycle. In addition, T-notes fell after today's news that showed US Q1 nonfarm productivity was revised downward and Q1 unit labor costs were revised higher. T-notes today initially moved higher when weekly US jobless claims unexpectedly rose to a 7-3/4 month high, a sign of labor market weakness and a dovish factor for Fed policy. Also, an easing in inflation expectations is bullish for T-notes after the US 10-year breakeven inflation rate fell to a 3-week low today at 2.297%. European government bond yields today are moving higher. The 10-year German bund yield rebounded from a 4-week low of 2.476% and is up +5.8 bp to 2.587%. The 10-year UK gilt yield rebounded from a 3-1/2 week low of 4.554% and is up +2.1 bp to 4.628%. Eurozone Apr PPI fell -2.2% m/m and rose +0.7% y/y, weaker than expectations of -2.1% m/m and +1.1% y/y. German Apr factory orders unexpectedly rose +0.6% m/m, stronger than expectations of -1.5% m/m. The ECB, as expected, cut the deposit facility rate by -25 bp to 2.00% from 2.25% and said, 'Inflation is currently at around the Governing Council's 2% medium-term target.' ECB President Lagarde said risks to growth 'tilted to the downside' as recent survey data points to weaker near-term prospects for the Eurozone economy. However, a stronger labor market and rising incomes will help the economy, and she wouldn't exclude further upward revisions to growth. She added that the ECB is getting toward the end of its rate cut cycle with today's rate cut. Swaps are discounting the chances at 42% for a -25 bp rate cut by the ECB at the July 24 policy meeting. US Stock Movers The strength of chip makers is supportive of the broader market. Micron Technology (MU) is up more than +4% to lead gainers in the Nasdaq 100. Also, ARM Holdings NV (ARM), Texas Instruments (TXN), ASML Holding NV (ASML), Applied Materials (AMAT), and Microchip Technology (MCHP) are up more than +1%. In addition, Lam Research (LRCX) and Analog Devices (ADI) are up more than +0.90%. Mining stocks are climbing today as the price of gold rose to a 4-week high and silver prices soared to a 13-year high. As a result, Freeport-McMoRan (FCX) is up more than +4%, and Anglogold Ashanti Plc (AU) is up more than +1%. MongoDB (MDB) is up more than +15% after reporting Q1 adjusted EPS of $1.06, well above the consensus of 67 cents, and raising its 2026 adjusted EPS forecast to $2.94-$3.12 from a previous estimate of $2.44-$2.62, stronger than the consensus of $2.60. Five Below (FIVE) is up more than +7% after reporting Q1 comparable sales rose +7.1%, better than the consensus of +6.37%, and forecast 2026 comparable sales will climb +3% to +5%, the midpoint above the consensus of +3.78%. Dollar Tree (DLTR) is up more than +7% to lead gainers in the S&P 500 after JPMorgan Chase upgraded the stock to overweight from neutral with a price target of $111. Verint Systems (VRNT) is up more than +6% after reporting Q1 adjusted EPS of 29 cents, better than the consensus of 19 cents. Brown-Forman (BF.B) is down more than -17% to lead losers in the S&P 500 after reporting Q4 net sales of $894 million, well below the consensus of $968.4 million. PVH Corp (PVH) is down more than -17% after cutting its 2026 adjusted EPS forecast to $10.75-$1.00 from a previous forecast of $12.40-$12.75, well below the consensus of $12.46. Ciena Corp (CIEN) is down more than -11% after reporting Q2 adjusted EPS of 42 cents, weaker than the consensus of 52 cents. Tesla (TSLA) is down more than -3% to lead losers in the Nasdaq 100, adding to Wednesday's -4% slide, after reporting its May vehicle shipments from China fell -15% y/y to 61,662 units, the eighth straight monthly decline. Costco Wholesale (COST) is down more than -2% after reporting May total comparable sales rose +4.3%, weaker than the consensus of +4.7% Procter & Gamble (PG) is down more than -1% to lead losers in the Dow Jones Industrials after announcing it expects to take a $1.6 billion charge over the next two years as it cuts its workforce by 7,000 or 15%. Earnings Reports (6/5/2025) Broadcom Inc (AVGO), Brown-Forman Corp (BF/B), Ciena Corp (CIEN), Docusign Inc (DOCU), Lululemon Athletica Inc (LULU), Toro Co/The (TTC), Vail Resorts Inc (MTN).
